{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:17:23Z","timestamp":1785410243890,"version":"3.56.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physiology & Behavior"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.physbeh.2023.114134","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T20:49:30Z","timestamp":1676839770000},"page":"114134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation"],"prefix":"10.1016","volume":"263","author":[{"given":"Bo","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Xian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Da","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.physbeh.2023.114134_bib0001","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.physbeh.2023.114134_bib0002","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1474-4422(18)30490-3","article-title":"The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications","volume":"18","author":"Arranz","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.physbeh.2023.114134_bib0003","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.brainresbull.2020.08.001","article-title":"Sodium orthovanadate improves learning and memory in intracerebroventricular-streptozotocin rat model of Alzheimer's disease through modulation of brain insulin resistance induced tau pathology","volume":"164","author":"Akhtar","year":"2020","journal-title":"Brain Res. Bull."},{"issue":"1","key":"10.1016\/j.physbeh.2023.114134_bib0004","first-page":"S76","article-title":"Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease","volume":"10","author":"Ferreira","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.physbeh.2023.114134_bib0005","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.physbeh.2023.114134_bib0006","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.euroneuro.2014.06.008","article-title":"Type 3 diabetes is sporadic Alzheimers disease: mini-review","volume":"24","author":"de la Monte","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.physbeh.2023.114134_bib0007","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212264","article-title":"Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents","volume":"3","author":"Vivian","year":"2014","journal-title":"Drugs Context"},{"key":"10.1016\/j.physbeh.2023.114134_bib0008","series-title":"Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors","author":"Padda","year":"2022"},{"issue":"1","key":"10.1016\/j.physbeh.2023.114134_bib0009","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-020-00607-4","article-title":"Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes","volume":"12","author":"Hierro-Bujalance","year":"2020","journal-title":"Alzheimers Res .Ther."},{"key":"10.1016\/j.physbeh.2023.114134_bib0010","doi-asserted-by":"crossref","DOI":"10.1007\/s10787-022-00973-5","article-title":"Dapagliflozin as an autophagic enhancer via LKB1\/AMPK\/SIRT1 pathway in ovariectomized\/D-galactose Alzheimer's rat model","author":"Ibrahim","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.physbeh.2023.114134_bib0011","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2017.08.013","article-title":"Canagliflozin prevents scopolamine-induced memory impairment in rats: comparison with galantamine hydrobromide action","volume":"277","author":"Arafa","year":"2017","journal-title":"Chem. Biol. Interact."},{"issue":"7","key":"10.1016\/j.physbeh.2023.114134_bib0012","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer's disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.physbeh.2023.114134_bib0013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12929-017-0355-7","article-title":"Drug candidates in clinical trials for Alzheimer's disease","volume":"24","author":"Hung","year":"2017","journal-title":"J. Biomed. Sci."},{"issue":"2","key":"10.1016\/j.physbeh.2023.114134_bib0014","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/138161206775193127","article-title":"The peripheral anionic site of acetylcholinesterase: structure, functions and potential role in rational drug design","volume":"12","author":"Johnson","year":"2006","journal-title":"Curr. Pharm. Des."},{"issue":"17","key":"10.1016\/j.physbeh.2023.114134_bib0015","doi-asserted-by":"crossref","first-page":"6490","DOI":"10.1021\/jm100573q","article-title":"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology","volume":"53","author":"Chaudhaery","year":"2010","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.physbeh.2023.114134_bib0016","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1002\/jcb.26036","article-title":"Molecular interaction of anti-diabetic drugs with acetylcholinesterase and sodium glucose Co-transporter 2","volume":"118","author":"Shakil","year":"2017","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.physbeh.2023.114134_bib0017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JAD-2006-9102","article-title":"Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease","volume":"9","author":"Lester-Coll","year":"2006","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.physbeh.2023.114134_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2020.117498","article-title":"Synchronous nonmonotonic changes in functional connectivity and white matter integrity in a rat model of sporadic Alzheimer's disease","volume":"225","author":"Tristao Pereira","year":"2021","journal-title":"Neuroimage"},{"issue":"1","key":"10.1016\/j.physbeh.2023.114134_bib0019","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0165-0270(84)90007-4","article-title":"Developments of a water-maze procedure for studying spatial learning in the rat","volume":"11","author":"Morris","year":"1984","journal-title":"J. Neurosci. Methods"},{"issue":"4","key":"10.1016\/j.physbeh.2023.114134_bib0020","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.neuropharm.2009.01.005","article-title":"A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia","volume":"56","author":"Agrawal","year":"2009","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.physbeh.2023.114134_bib0021","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10072-013-1594-3","article-title":"Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ induced dementia model of rats","volume":"35","author":"Yang","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.physbeh.2023.114134_bib0022","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.physbeh.2023.114134_bib0023","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/hmg\/ddl066","article-title":"Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression","volume":"15","author":"Manczak","year":"2006","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.physbeh.2023.114134_bib0024","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3233\/JAD-160869","article-title":"Treadmill exercise exerts neuroprotection and regulates microglial polarization and oxidative stress in a streptozotocin-induced rat model of sporadic alzheimer's disease","volume":"56","author":"Lu","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.physbeh.2023.114134_bib0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3233\/JAD-2010-091729","article-title":"Modulation of hydrogen peroxide and acrolein-induced oxidative stress, mitochondrial dysfunctions and redox regulated pathways by the Bacopa monniera extract: potential implication in Alzheimer's disease","volume":"21","author":"Singh","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.physbeh.2023.114134_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","author":"Kopp","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.physbeh.2023.114134_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105876","article-title":"AdipoRon induces AMPK activation and ameliorates Alzheimer's like pathologies and associated cognitive impairment in APP\/PS1 mice","volume":"174","author":"Khandelwal","year":"2022","journal-title":"Neurobiol. Dis."},{"issue":"13","key":"10.1016\/j.physbeh.2023.114134_bib0028","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019995","article-title":"Effects of sodium-glucose linked transporter 2 inhibition with ertugliflozin on mitochondrial function, energetics, and metabolic gene expression in the presence and absence of diabetes mellitus in mice","volume":"10","author":"Croteau","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.physbeh.2023.114134_bib0029","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s12264-013-1415-y","article-title":"Tau hyperphosphorylation induces apoptotic escape and triggers neurodegeneration in Alzheimer's disease","volume":"30","author":"Wang","year":"2014","journal-title":"Neurosci. Bull."},{"issue":"2","key":"10.1016\/j.physbeh.2023.114134_bib0030","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1006\/nbdi.2002.0549","article-title":"Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain","volume":"11","author":"Rohn","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.physbeh.2023.114134_bib0031","first-page":"1","article-title":"Effects and mechanisms of natural products on Alzheimer's disease","author":"Yang","year":"2021","journal-title":"Crit. Rev. Food Sci. Nutr."},{"issue":"11","key":"10.1016\/j.physbeh.2023.114134_bib0032","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/dom.14814","article-title":"The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis","volume":"24","author":"Moellmann","year":"2022","journal-title":"Diabetes, Obes. Metabolism"},{"issue":"2","key":"10.1016\/j.physbeh.2023.114134_bib0033","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/alzrt74","article-title":"Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-beta toxicity","volume":"3","author":"Eckert","year":"2011","journal-title":"Alzheimers Res. Ther."},{"issue":"5782","key":"10.1016\/j.physbeh.2023.114134_bib0034","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1126\/science.1130481","article-title":"Cell signaling. H2O2, a necessary evil for cell signaling","volume":"312","author":"Rhee","year":"2006","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.physbeh.2023.114134_bib0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mehy.2003.12.045","article-title":"A \"mitochondrial cascade hypothesis\" for sporadic alzheimer's disease","volume":"63","author":"Swerdlow","year":"2004","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.physbeh.2023.114134_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114578","article-title":"GLP-1 improves the neuronal supportive ability of astrocytes in Alzheimer's disease by regulating mitochondrial dysfunction via the cAMP\/PKA pathway","volume":"188","author":"Xie","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.physbeh.2023.114134_bib0037","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3233\/JAD-160702","article-title":"Mitochondrial dysfunction and synaptic transmission failure in alzheimer's disease","volume":"57","author":"Guo","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"5","key":"10.1016\/j.physbeh.2023.114134_bib0038","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hipo.10109","article-title":"Rapid induction of BDNF expression in the hippocampus during immobilization stress challenge in adult rats","volume":"13","author":"Marmigere","year":"2003","journal-title":"Hippocampus"},{"issue":"6","key":"10.1016\/j.physbeh.2023.114134_bib0039","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.celrep.2018.07.020","article-title":"Genetic dissection of presynaptic and postsynaptic BDNF-TrkB signaling in synaptic efficacy of CA3-CA1 synapses","volume":"24","author":"Lin","year":"2018","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.physbeh.2023.114134_bib0040","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/jnr.20077","article-title":"Exercise induces BDNF and synapsin I to specific hippocampal subfields","volume":"76","author":"Vaynman","year":"2004","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.physbeh.2023.114134_bib0041","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/path.5056","article-title":"The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease","volume":"245","author":"Batista","year":"2018","journal-title":"J. Pathol."},{"key":"10.1016\/j.physbeh.2023.114134_bib0042","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"issue":"4","key":"10.1016\/j.physbeh.2023.114134_bib0043","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1007\/s13311-021-01140-4","article-title":"Crosstalk among NLRP3 inflammasome, ETBR signaling, and miRNAs in stress-induced depression-like behavior: a modulatory role for SGLT2 inhibitors","volume":"18","author":"Muhammad","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"19","key":"10.1016\/j.physbeh.2023.114134_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911311","article-title":"Medicinal herbs and their derived ingredients protect against cognitive decline in in vivo models of alzheimer's disease","volume":"23","author":"Tsai","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.physbeh.2023.114134_bib0045","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI57256","article-title":"An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers","volume":"122","author":"Bomfim","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.physbeh.2023.114134_bib0046","article-title":"Tau Phosphorylation by GSK3 in Different Conditions","volume":"2012","author":"Avila","year":"2012","journal-title":"Int. J. Alzheimers Dis"},{"issue":"5","key":"10.1016\/j.physbeh.2023.114134_bib0047","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1586\/ern.10.40","article-title":"Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors","volume":"10","author":"Avila","year":"2010","journal-title":"Expert. Rev. Neurother."},{"issue":"4","key":"10.1016\/j.physbeh.2023.114134_bib0048","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-018-0878-6","article-title":"Ertugliflozin: first Global Approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.physbeh.2023.114134_bib0049","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2147\/TCRM.S137068","article-title":"Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes","volume":"14","author":"Derosa","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"issue":"2","key":"10.1016\/j.physbeh.2023.114134_bib0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/17446651.2019.1571908","article-title":"Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes","volume":"14","author":"Frias","year":"2019","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"10.1016\/j.physbeh.2023.114134_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106062","article-title":"Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment","volume":"176","author":"Rizzo","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.physbeh.2023.114134_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.708547","article-title":"Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus","volume":"15","author":"Sim","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.physbeh.2023.114134_bib0053","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/384017","article-title":"Insulin in central nervous system: more than just a peripheral hormone","volume":"2012","author":"Duarte","year":"2012","journal-title":"J. Aging Res."},{"key":"10.1016\/j.physbeh.2023.114134_bib0054","first-page":"141","article-title":"12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus","volume":"10","author":"Perna","year":"2018","journal-title":"Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.physbeh.2023.114134_bib0055","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40262-020-00875-1","article-title":"Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor","volume":"59","author":"Fediuk","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.physbeh.2023.114134_bib0056","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s00125-020-05133-4","article-title":"Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials","volume":"63","author":"Cherney","year":"2020","journal-title":"Diabetologia"}],"container-title":["Physiology & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938423000628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031938423000628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:26:20Z","timestamp":1758479180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031938423000628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":56,"alternative-id":["S0031938423000628"],"URL":"https:\/\/doi.org\/10.1016\/j.physbeh.2023.114134","relation":{},"ISSN":["0031-9384"],"issn-type":[{"value":"0031-9384","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation","name":"articletitle","label":"Article Title"},{"value":"Physiology & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.physbeh.2023.114134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114134"}}